Study to evaluate the impact of the ER/LA opioid REMS program on the incidence of Emergency Department visits and hospitalizations for overdose/poisoning and death among patients prescribed ER/LA opioid analgesics.
As part of the FDA-approved plan to evaluate the effects of the REMS program, the REMS Program Companies (RPC) are required to submit FDA assessment reports on a regular basis. The present study is one of several program evaluation components carried out in support Assessment 5: Surveillance monitoring for misuse, abuse, overdose, addiction, death and intervention taken. This study will evaluate the impact of the ER/LA opioid REMS program on the incidence of ED visits and hospitalizations for overdose/poisoning and death among patients prescribed ER/LA opioid analgesics.
Study Type
OBSERVATIONAL
Enrollment
183,452
Number of ED visits for opioid overdose/poisoning and mortality
Time frame: Retrospective review over period from July 2010 through December 2014
Number of hospitalizations for opioid overdose/poisoning and mortality
Time frame: Retrospective review over period from July 2010 through December 2014
All-cause mortality
Time frame: Retrospective review over period from July 2010 through December 2014
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.